Jefferies Maintains 'Buy' Rating on CVS Health Corporation (CVS); Raises PT

Billionaire Kerr Neilson has bought over $290,715 worth of shares in CVS Health Corporation (NYSE:CVS), representing 0.02% of his stock portfolio, securing the company a spot in Billionaire Kerr Neilson’s 10 Stock Picks with Huge Upside Potential.

On June 30, 2025, Jefferies increased its price target on CVS Health Corporation (NYSE:CVS) from $74 to $80. The analyst attributed this to the management’s conservative future guidance, along with expectations for potential upside in the company’s EPS. Despite the sector headwinds, CVS remains one of the large-cap healthcare picks in the analyst’s portfolio.

For Q1 2025, CVS Health Corporation (NYSE:CVS) reported $95 billion in revenue, which was a 7% YoY increase. Meanwhile, its adjusted EPS was $2.25 per share and adjusted earnings were $4.6 billion. As per the company’s full-year guidance, EPS is estimated within the range of $6 and $6.2.

CVS Health Corporation (NYSE:CVS) offers insurance, pharmacy benefit management (PBM), and retail pharmacy services. It does so through its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.

While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  7 Best Stocks to Invest in for a Quick Return and 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

Disclosure: None.